Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
New Drug Application
Biotech
Corcept's phase 3 cancer win sends stock skyrocketing 85%
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone.
Gabrielle Masson
Mar 31, 2025 10:25am
2 eye disease biotechs merge, set sights on FDA approval
Dec 12, 2024 11:05am
Elevar offers $500M biobucks for Relay's rare cancer asset
Dec 3, 2024 3:04pm
Aldeyra preps for FDA refiling as dry eye drug hits ph. 3 goal
Aug 8, 2024 10:48am
Vertex inches closer to acute pain market as FDA accepts VX-548
Apr 18, 2024 10:50am
Milestone resubmits NDA, Aldeyra readies 2nd chance filing
Mar 28, 2024 10:40am
